William G. Wierda
0000-0002-7357-270X
Publication & Citation Trends
Publications
0 total
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
Cited by 0
Semantic Scholar
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy
Cited by 0
Semantic Scholar
Favorable Real-World Outcomes of Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia
Cited by 0
Semantic Scholar
The Care and Cure of the Leukemias in 2026
Cited by 0
Semantic Scholar
Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study.
Cited by 0
Semantic Scholar
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.
Cited by 1
Semantic Scholar
Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials
Cited by 0
Semantic Scholar
Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion
Cited by 0
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(1183)
Lymphoma Diagnosis and Treatment
(528)
Chronic Myeloid Leukemia Treatments
(321)
Acute Lymphoblastic Leukemia research
(320)
Immunodeficiency and Autoimmune Disorders
(215)
Affiliations
University of Maryland, Baltimore
Roswell Park Comprehensive Cancer Center
National Institutes of Health
Hackensack University Medical Center
Karolinska University Hospital